scholarly journals Nab-paclitaxel as alternative treatment regimen in advanced cholangiocellular carcinoma

2016 ◽  
Vol 7 (4) ◽  
pp. 588-594 ◽  
Author(s):  
Matthias Unseld ◽  
Werner Scheithauer ◽  
Roman Weigl ◽  
Gabriela Kornek ◽  
Nadja Stranzl ◽  
...  
Keyword(s):  
Treatment Regimen ◽  
Alternative Treatment ◽  
Cholangiocellular Carcinoma

scholarly journals Camel milk as an alternative treatment regimen for diabetes therapy

2021 ◽  
Author(s):  
Humaira Hussain ◽  
Feroza Hamid Wattoo ◽  
Muhammad Hamid Sarwar Wattoo ◽  
Muhammad Gulfraz ◽  
Tariq Masud ◽  
...  
Keyword(s):  
Treatment Regimen ◽  
Alternative Treatment ◽  
Camel Milk ◽  
Diabetes Therapy

scholarly journals Control of Metastatic Tumor Growth in a Patient with Sporadic Metastatic Malignant Peripheral Nerve Sheath Tumor (sMPNST) Using the Hope Protocol, an Alternative Treatment Regimen for Cancer

2021 ◽  
Vol 8 ◽  
Author(s):  
Erlinda Gordon ◽  
Jonathan Dang ◽  
Nicole L. Angel ◽  
Don A. Brigham ◽  
Lance Ostendorf ◽  
...  
Keyword(s):  
Case Report ◽  
Peripheral Nerve ◽  
Tumor Growth ◽  
Treatment Regimen ◽  
Alternative Treatment ◽  
Metastatic Tumor ◽  
Nerve Sheath Tumor ◽  
Peripheral Nerve Sheath Tumor ◽  
Nerve Sheath ◽  
One Year

Metastatic sporadic malignant peripheral nerve sheath tumor (sMPNST) is associated with only 17% five-year survival rate using standard chemotherapy and there are no 10-year survival reports with the exception of a case report wherein a patient with metastatic sMPNST is still alive with no active disease and on no further cancer therapy, >12 years from DeltaRex-G treatment initiation. In this case report, we describe an interim alternative treatment regimen designed and used by a patient with metastatic sMPNST, while awaiting the return, GMP bioproduction, and QC certification of DeltaRex-G as a potential treatment option. We report on the successful control of metastatic tumor growth over a one-year treatment period using the Hope Protocol consisting of artemisinin, curcumin, cannabis oil, disulfiram, fenbendazole, mebendazole, albendazole, atorvastatin, doxycycline, vitamin C, vitamin E, a plant-based diet, sans refined sugar, yoga, acupuncture, meditation, exercise and hot sauna, and we discuss their biochemical mechanisms of action.

An alternative treatment regimen of advanced seminoma with carboplatin, etoposide, and bleomycin instead of cisplatin-based therapy

2013 ◽  
Vol 31 (1) ◽  
pp. 110-114
Author(s):  
Eva Giesen ◽  
Alet Mager ◽  
Harm van Tinteren ◽  
Sjoerd Rodenhuis ◽  
J. Martijn Kerst
Keyword(s):  
Treatment Regimen ◽  
Alternative Treatment

Analysis of high-dose methotrexate with rituximab versus other treatment regimens for primary central nervous system (CNS) lymphoma.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 2090-2090
Author(s):  
Scott Michael Lindhorst ◽  
Frances McSherry ◽  
Annick Desjardins ◽  
Henry S. Friedman ◽  
Katherine B. Peters
Keyword(s):  
Treatment Regimen ◽  
Alternative Treatment ◽  
Survival Rates ◽  
Primary Cns Lymphoma ◽  
Cns Lymphoma ◽  
P Value ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Treatment Regimens ◽  
Dose Methotrexate

2090 Background: The most effective and least toxic treatment regimen for primary CNS lymphoma is a matter of debate. Most current regimens utilize various doses of high-dose methotrexate combined with other agents. The utility of deferred radiation is also under study. Methods: We evaluated 28 patients with primary CNS lymphoma treated with methotrexate 3.5 g/m2 and rituximab, as well as alternative regimens. Median, 12-month, and 24-month survival were compared for the various treatment regimens, as well as for patients who received radiation and those who did not. Results: Survival rates were significantly better in the methotrexate-rituximab treatment cohort than the other regimens examined (Log-Rank p-value 0.0437). 12-month survival for the methotrexate-rituximab cohort was 72.7% (95% CI, 37.1% to 90.3%) versus the alternative treatment cohort 12-month survival of 49.4% (95% CI, 23.7% to 70.8%). 24-month survival for the methotrexate-rituximab cohort was 72.7% (95% CI, 37.1% to 90.3%) versus the alternative treatment cohort 24-month survival of 39.5% (95% CI, 14.9% to 63.6%). Median survival for the alternative treatment cohort was 11 months (95% CI, 2.2 to 28.6), while the median survival for the methotrexate-rituximab regimen was not reached. Stratified by radiation, survival rates were significantly better in the radiation cohort than the cohort without radiation (Log-Rank p-value 0.0040). 12-month survival for the radiation cohort was 90% (95% CI, 47.3% to 98.5%) versus the cohort without radiation 12-month survival of 40.5% (95% CI, 17.7% to 62.3%). 24-month survival for the radiation cohort was 90% (95% CI, 47.3% to 98.5%) versus the cohort without radiation 24-month survival of 33.7% (95% CI, 12.9% to 56.1%). Median follow-up for all patients was 21.5 months (95% CI, 16 to 42.1). Conclusions: The combination of methotrexate at 3.5 g/m2 with rituximab is a valid treatment regimen for primary CNS lymphoma. Patients may be spared toxicity by using a methotrexate dose of 3.5 g/m2 rather than 8 g/m2. The addition of radiation provided a significant survival advantage in this observational study, however, radiation deferred until progression may be a viable alternative.

scholarly journals EFFICIENCY AND PERFORMANCE OF THE USE OF RECOMBINANT INTERFERON GAMMA IN COMPLEX THERAPY OF INFLUENZA A(H1N1)PDM09 PATIENTS

2017 ◽  
Vol 22 (2) ◽  
pp. 58-63
Author(s):  
T. V Sologub ◽  
A. S Midikari ◽  
V. N Agafonov ◽  
A. A Suzdalcev ◽  
V. V Tsvetkov
Keyword(s):  
Treatment Regimen ◽  
Interferon Gamma ◽  
Alternative Treatment ◽  
Influenza A ◽  
Economic Feasibility ◽  
Control Group ◽  
Recombinant Interferon ◽  
Treatment Regimens ◽  
Influenza A H1n1 ◽  
Complex Therapy

In the period of the epidemic rise in the incidence rate of influenza in 2015-2016 on the basis of infectious hospitals in Simferopol, Arkhangelsk and Samara, there performed a multicenter to evaluate the effectiveness and economic feasibility of two alternative treatment regimens for influenza A (H1N1) pdm09 patients. The study included 88 patients with a laboratory-confirmed diagnosis of influenza A (H1N1)pdm09. Patients of the main group (n = 46) received complex therapy with the use of antiviral (oseltamivir) and immunomodulating (interferon gamma) agents. Patients of the control group (n = 40) received only antiviral therapy (oseltamivir). To assess the effectiveness and economic feasibility of the two different treatment regimens, the outcome of the disease was analyzed: the discharge the hospital up to the 10th day of the illness and no symptoms of the disease by the 3-6th day of treatment. The supplementation of recombinant interferon gamma in the treatment regimen of influenza A (H1N1) pdm09 patients was found to promote the faster release of catarrhal and respiratory symptoms of the disease: the absence of dry cough by the 3-6th day of treatment (RR = 1.43, 95% CI: 0.86 - 2.38), rhinitis (RR 1.21, 95% CI 1.05-1.40) and dyspnea (RR= 1.28, 95% CI: 1.06-1.54). In addition, the supplementation of recombinant interferon gamma in the treatment regimen of patients with influenza A (H1N1)pdm09 promoted a significant shortening of time of the recovery and discharge from the hospital (RR =1.39, 95% CI: 0.97 - 2.00). Clinical and economic analysis of the use of two alternative treatment regimens has shown the supplementation of recombinant interferon gamma in the therapy of influenza A (H1N1) pdm09 patients to be economically favorable

scholarly journals S2738 An Alternative Treatment Regimen in Chronic Pembrolizumab Use Induced Autoimmune Hepatitis

2021 ◽  
Vol 116 (1) ◽  
pp. S1145-S1145
Author(s):  
Atul Sinha ◽  
Deepthi Kagolanu ◽  
Nausheer Khan ◽  
Kaleem Rizvon
Keyword(s):  
Autoimmune Hepatitis ◽  
Treatment Regimen ◽  
Alternative Treatment

scholarly journals Should High-dose Daptomycin be an Alternative Treatment Regimen for Enterococcal Endocarditis?

2019 ◽  
Vol 8 (4) ◽  
pp. 695-702 ◽  
Author(s):  
Maddalena Peghin ◽  
Alessandro Russo ◽  
Filippo Givone ◽  
Martina Ingani ◽  
Elena Graziano ◽  
...  
Keyword(s):  
Treatment Regimen ◽  
Alternative Treatment ◽  
High Dose
Sign in / Sign up

Export Citation Format

Share Document